

Investor Presentation

Nasdaq: STRM



Disclosure Statement

SAFE HARBOR STATEMENT: FORWARD-LOOKING DISCLOSURE

This presentation contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, based on current management expectations. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and that can cause Streamline Health's actual results to differ. We caution you therefore to not place undue reliance on such statements.

Actual results might differ materially from these statements due to a number of risks and uncertainties. Risks that may contribute to the uncertain nature of these statements are described in Streamline Health's periodic filings made with Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." Streamline Health undertakes no obligation to update any forward-looking statements or relevant risks, except as may be required by law.


TRADEMARKS

Product or company names referenced herein may be trademarks or registered trademarks of their respective owners




Streamline Health Investment Highlights

Transforming hospital revenue cycle management



Paradigm-shifting eValuator™ Revenue Integrity Program

Leading an industry movement to automated pre-bill coding analysis



Recent Acquisition of Avelead & the RevID Solution

Driving pre-billing charge verification to prevent revenue leakage



Rapidly expanding SaaS revenue: 59% Growth of SaaS Revenue in 2Q21 vs 2Q20

Driven by significant eValuator Growth



Positioned for Growth in 2021 and Beyond

Despite COVID-19 impact, recent strategic evolution positions STRM for long-term top-line growth



The Hospital Revenue Cycle is Wildly Inefficient

Hospital billing efficiency is throttled by its coders' ability to navigate the complexities of ICD-10 – a classification system with >130,000 unique codes, based on limited, inconsistent information from clinical staff.

Poor documentation verification and erroneous coding contributes to substantial revenue leakage while overbilling can result in denials, claw-backs and fines that further hinder financial performance.



- Coding Complexity
 >130,000 unique billing codes
- Regulatory Complexity
 Coding errors can result in missed
 revenue or create regulatory risks
- Tremendous Urgency
 Hospitals need an army of coders to keep up with demand. Each day a case isn't billed negatively impacts cash flow
- Minimal Auditing

 Most providers audit only a handful of cases and primarily after they've been billed

PROVIDERS ARE FORCED TO SACRIFICE CODING QUALITY FOR EXPEDIENCY

We Streamline Revenue Cycle Management

Our SaaS-based tools and tech-enabled services relieve the financial pressure on hospitals by transforming clinical data into compliant revenue.

Our innovative software solutions, like RevID™ and eValuator™ improve documentation and coding accuracy, resulting in optimized cash flow and improved financial performance.



Patient Record




Output from any Hospital EHR System (Cerner, Epic, Allscripts)

△ 00 Org

Organize

Abstracting & Physician Query



Optimize

Clinical Documentation Improvement (CDI) & RevIDTM




Evaluate

eValuator™ cloudbased pre-bill coding analysis





Unique Offerings in a Growing Industry



\$900M+

Total Addressable Market for Streamline's marketed SaaS software solutions in the US across 579 accounts



Improving Healthcare Provider Financial Performance

Leading an Industry Movement to Pre-Bill Coding Optimization with eValuatorTM

Financial Performance is Dictated by Coding Accuracy

Current Approach

2-4%

Pre- or post-bill audits of 2-4% of cases

- I Small number of randomly selected cases
- Limited window to resubmit for missed revenue or correct overbilling
- No opportunity to optimize 95% of cases

New Best Practice

100%

Automated pre-bill analysis of Every Record

- Identifies coding issues that indicate revenue leakage and compliance exposure
- Routes to auditor, with recommended corrections
- All prior to billing with virtually no impact on DNFB



How Automated Pre-Bill Coding Analysis Impacts Revenue

	Documentation Confirms	Initial Coding Reflects	Submitted Coding	Reimbursement
Patient A (No Safety Net)	 COVID-19 Shortness of breath Congestive heart failure Diabetes with high blood sugar 	 COVID-19 Congestive heart failure Diabetes with hyperglycemia 	DRG-179	\$7,504
Patient B (eValuator™ Optimized)	 COVID-19 Shortness of breath is due to acute exacerbation of chronic congestive heart failure Diabetes with high blood sugar 	 COVID-19 Acute on chronic congestive heart failure (MCC) Diabetes with hyperglycemia 	DRG-177	\$14,355



Joining the Movement to Pre-Bill Financial Improvement

Providers of All Sizes See Strong ROI in terms of Net-New Compliant Revenue Capture

IM Health Fairview (Minneapolis, MN) ≥2,276 Beds; IP and OP (Epic)	HEALTH	11.6x
I Memorial Hermann (Houston, TX) ▶4,000 Beds; IP and OP (Cerner)	MEMORIAI HERMANN	20.2x
I University of Louisville (Louisville, KY) ▶1,209 Beds; IP and OP (Cerner/Allscripts)	U-L Health	5.4x
Cooper University (Camden, NJ) ▶574 Beds; IP (Epic)	© Cooper University Health Care	7.6x
Vidant Health (Greenville, NC) ▷ 1,297 Beds; IP and OP (Epic)	VIDANT HEALTH™	6.6x



ROI in Net-New Revenue

Avelead Overview



Technology solutions that automate and improve the revenue cycle

- **EHR-agnostic** suite of revenue cycle solutions that help healthcare providers capture **100%** of the revenue they've earned.
- Flagship **RevID** solution compares posted charges to clinical information and is an ideal complement to eValuator
- SaaS ARR run rate of \$5.7M, TTM revenue of \$10.2M as of 6/30/21
- Anticipate FY21 SaaS revenues doubling compared to FY20
- Strong relationship with Cerner




Improving Revenue Reconciliation with RevID




Cloud-based Identification of Charge Capture Discrepancies



Eliminates revenue leakage before claims are processed.



Utilizes proprietary algorithms to compare posted charges/billing against clinical information.



Streamlines workflow by automating the revenue cycle.



How Automated Charge Reconciliation Impacts Revenue





Initial Charge Capture	Submitted for Billing	Impact
Primarily manual review limited by staff member's knowledge, attention to detail and other factors	Incomplete claims don't request reimbursement for missed services	Revenue leakage drains millions in legitimate income
Automation using algorithms compares all posted charges against documentation & billing	Corrected claims accurately reflect all provided services and subsequent charges are billed	Accurate bills ensure optimized financial performance



data

Financial Results

2Q21 Income Statement – Exclusive of Avelead

	Three Months Ended July 31, 2021	Three Months Ended July 31, 2020
Revenue	\$2.9M	\$2.9M
Operating Expenses (including transaction costs)	\$5.3M	\$4.1M
Loss From Continuing Operations (including transaction costs and forgiveness of PPP Loan)	(\$0.1M)	(\$1.2M)
Net Income/(Loss)	(\$0.1M)	(\$1.1M)
Adj. EBITDA*	(\$0.8M)	(\$0.4M)

^{*}Streamline Health defines "adjusted EBITDA" as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees. Please see our press release for a reconciliation of non-GAAP Adjusted EBITDA to GAAP Net Income.



Clean Capital Structure

Cash & cash equivalents (as of 7/31/21)

\$15.8M (\$3M of cash used for 8/16 acquisition: \$13M purchase price and transaction cost net of \$10M term loan)

Debt(as of 7/31/21)

\$0M (\$10M 5-year term loan with favorable repayment terms entered into in conjunction with 8/16 acquisition)

Common Stock (as of 9/9/21)

47.7M shares outstanding (5M of shares issued in conjunction with 8/16 acquisition)





Investor Presentation

Nasdaq: STRM

